Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, Kymera Therapeutics Inc (NASDAQ: KYMR) closed at $62.89 up 7.95% from its previous closing price of $58.26. In other words, the price has increased by $7.95 from its previous closing price. On the day, 0.8 million shares were traded. KYMR stock price reached its highest trading level at $63.29 during the session, while it also had its lowest trading level at $58.0.
Ratios:
For a deeper understanding of Kymera Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.32 and its Current Ratio is at 8.32. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on September 18, 2025, Reiterated its Buy rating but revised its target price to $70 from $60 previously.
On September 17, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $60.
On September 16, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $70.RBC Capital Mkts initiated its Outperform rating on September 16, 2025, with a $70 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 15 ’25 when Gollob Jared sold 59,576 shares for $61.42 per share. The transaction valued at 3,659,254 led to the insider holds 109,992 shares of the business.
Jared Gollob bought 59,576 shares of KYMR for $3,470,898 on Oct 15 ’25. On Oct 13 ’25, another insider, Gollob Jared, who serves as the Chief Medical Officer of the company, sold 3,114 shares for $60.00 each. As a result, the insider received 186,840 and left with 118,359 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYMR now has a Market Capitalization of 4496483840 and an Enterprise Value of 3916752896. For the stock, the TTM Price-to-Sale (P/S) ratio is 100.57 while its Price-to-Book (P/B) ratio in mrq is 4.57. Its current Enterprise Value per Revenue stands at 87.602 whereas that against EBITDA is -12.839.
Stock Price History:
The Beta on a monthly basis for KYMR is 2.32, which has changed by 0.25967562 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, KYMR has reached a high of $60.00, while it has fallen to a 52-week low of $19.44. The 50-Day Moving Average of the stock is 30.85%, while the 200-Day Moving Average is calculated to be 57.96%.
Shares Statistics:
For the past three months, KYMR has traded an average of 721.02K shares per day and 665550 over the past ten days. A total of 70.56M shares are outstanding, with a floating share count of 59.07M. Insiders hold about 17.38% of the company’s shares, while institutions hold 95.06% stake in the company. Shares short for KYMR as of 1759190400 were 8085396 with a Short Ratio of 11.21, compared to 1756425600 on 8164580. Therefore, it implies a Short% of Shares Outstanding of 8085396 and a Short% of Float of 13.96.
